EAP-001: An Open-Label, Expanded Access Protocol for Firdapse Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS) and Downbeat Nystagmus.


The primary objective of the study is:
• To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available.

The secondary objective of the study is:
• To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus

More information

Contact us

To learn more about clinical trials at ProHealth Care, email research.institute@phci.org or call 262-928-3447.

Quick Access Links